Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial
Microperimetry demonstrates a reduced rate of visual function loss in the central macula and junctional zone with pegcetacoplan treatment in GA due to AMD.
Authors
- Roy Schwartz (ORCID: https://orcid.org/0000-0003-3487-5713)
- Frank Gerhard Holz (ORCID: https://orcid.org/0000-0001-8019-9272)
- Usha Chakravarthy (ORCID: https://orcid.org/0000-0002-2606-3734)
- Eric M. Moult
- Marco U Morales (ORCID: https://orcid.org/0000-0002-1508-2753)
- Caleb Bliss
- Nadia Khalida Waheed (ORCID: https://orcid.org/0000-0002-8229-7519)
- Stela Vujosevic (ORCID: https://orcid.org/0000-0001-6773-9967)
- Philip Lewis
- Robyn H. Guymer (ORCID: https://orcid.org/0000-0002-9441-4356)
- Aleksandra Rachitskaya (ORCID: https://orcid.org/0000-0001-5545-9474)
- Caroline R. Baumal (ORCID: https://orcid.org/0000-0002-3651-8210)
- A. Yasin Alibhai
- Hanne Vorwerk
Institutions
- Boston University (US)
- Cleveland Clinic (US)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Bonn (DE)
- University of Ulster (GB)
- University Hospital Bonn (DE)
- MultiMedica (IT)
- Group Image (Poland) (PL)
- Centre for Eye Research Australia (AU)
- Tower Semiconductor (Israel) (IL)
- Apellis Pharmaceuticals (United States) (US)
- Eye Center (SA)
- Royal Victoria Hospital (GB)
- Victoria Hospital (GB)
- Stadtwerke München (Germany) (DE)
- Moorfields Eye Hospital (GB)
- Trend Micro (Japan) (JP)
- University College London (GB)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- American Journal of Ophthalmology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1016/j.ajo.2025.02.012
- Citations
- 9
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 15.36
Funders
- Apellis Pharmaceuticals